Another GLP-1 Drug Access Model: Will a Co-Pay ...

By Rene Pretorius

May 26, 2025

High costs of GLP-1 receptor agonists like Wegovy and Zepbound—often exceeding $1,000 monthly—limit access for patients seeking effective obesity and diabetes treatments. These barriers fuel demand for innovativ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.